The slight EPS miss is secondary to the positive pipeline catalysts. Focus on the upcoming enozertinib data at ESMO October 2026 and the rinzimetostat program update in 2H 2026. The Bayer collaboration strengthens the Phase 3 trial setup without diluting ORIC's rights. Monitor cash burn rate relative to the runway into 2H 2028 and any further ATM activity.
Price Chart
Executive Summary
ORIC reported Q2 2026 net loss of $(0.38) per share, missing consensus of $(0.36) by $0.02. The operational highlight is the initiation of Himalayas-1, a global Phase 3 trial for rinzimetostat in metastatic castration-resistant prostate cancer, and a clinical collaboration with Bayer for darolutamide supply. Cash runway extends into 2H 2028, with key data catalysts expected in 2H 2026.
Key Financial Metrics
Key Facts
- Q2 2026 net loss $(0.38)/share vs consensus $(0.36), a -5.6% miss
- Initiated global Phase 3 registrational trial Himalayas-1 for rinzimetostat in mCRPC
- Entered clinical trial collaboration with Bayer to receive darolutamide at no cost for Himalayas-1
- Cash and investments $387.6M, expected runway into 2H 2028
- R&D expenses $36.3M, up 19% YoY due to rinzimetostat advancement
- Raised $59.9M via ATM in Q1 2026 from healthcare specialist funds
- Enozertinib 1L EGFR atypical monotherapy data expected at ESMO October 2026
Financial Impact
Net loss of $41.5M for Q2 2026, versus $36.4M in Q2 2025; EPS miss of $0.02 relative to consensus
Risk Factors
- Clinical trial risk for rinzimetostat Phase 3 (Himalayas-1) given competitive prostate cancer landscape
- Dilution risk from potential further ATM drawdowns
- Cash burn increasing as R&D expands with Phase 3 costs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3337877 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 3, 2026 8w ago | Press Release | $13.47 $12.89 | ▼ −4.31% | ▼ −3.07% | $12.26 (−8.98%) |
Jun 22, 2026 14w ago | 8-K | $8.91 $10.42 | ▲ +16.95% | ▲ +15.79% | $12.26 (+37.60%) |
Jun 11, 2026 16w ago | Institutional Cluster | $7.82 $10.94 | ▲ +39.90% | ▲ +38.01% | $12.26 (+56.78%) |
May 4, 2026 21w ago | 8-K | $9.57 $7.62 | ▼ −20.38% | ▼ −25.33% | $12.26 (+28.11%) |
Apr 3, 2026 25w ago | Press Release | $8.91 $9.63 | ▲ +8.08% | ▼ −0.90% | $12.26 (+37.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access